A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 184,100 shares of VKTX stock, worth $7.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
184,100
Previous 159,400 15.5%
Holding current value
$7.8 Million
Previous $8.45 Million 37.95%
% of portfolio
0.02%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$49.84 - $70.47 $1.23 Million - $1.74 Million
24,700 Added 15.5%
184,100 $11.7 Million
Q2 2024

Aug 09, 2024

BUY
$47.39 - $80.2 $7.55 Million - $12.8 Million
159,400 New
159,400 $8.45 Million
Q2 2023

Aug 11, 2023

SELL
$14.84 - $24.79 $10.5 Million - $17.5 Million
-704,200 Reduced 92.51%
57,000 $924,000
Q1 2023

May 12, 2023

SELL
$8.08 - $17.33 $1.53 Million - $3.28 Million
-189,400 Reduced 19.92%
761,200 $12.7 Million
Q4 2022

Feb 13, 2023

SELL
$2.72 - $9.4 $260,576 - $900,520
-95,800 Reduced 9.16%
950,600 $8.94 Million
Q3 2022

Nov 14, 2022

BUY
$2.55 - $3.89 $459,509 - $700,978
180,200 Added 20.8%
1,046,400 $2.85 Million
Q2 2022

Aug 12, 2022

SELL
$2.11 - $3.15 $213,424 - $318,619
-101,149 Reduced 10.46%
866,200 $2.5 Million
Q1 2022

May 13, 2022

BUY
$3.0 - $4.88 $2.17 Million - $3.54 Million
724,476 Added 298.29%
967,349 $2.9 Million
Q4 2021

Feb 11, 2022

BUY
$4.6 - $6.72 $1.12 Million - $1.63 Million
242,873 New
242,873 $1.12 Million
Q1 2021

May 13, 2021

SELL
$5.74 - $9.67 $1.03 Million - $1.73 Million
-179,000 Closed
0 $0
Q4 2020

Feb 10, 2021

BUY
$5.3 - $6.71 $752,070 - $952,149
141,900 Added 382.48%
179,000 $1.01 Million
Q3 2020

Nov 13, 2020

BUY
$5.73 - $8.11 $212,583 - $300,881
37,100 New
37,100 $216,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.25B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.